

Diagnostics as a Resistance Combatting Strategy

Robin Patel, M.D.

Elizabeth P. and Robert E. Allen Professor of Individualized Medicine
Professor of Medicine and Microbiology, Mayo Clinic College of Medicine

patel.robin@mayo.edu





70% Clinical Decisions Substantially Based on Results of Diagnostic Tests

LABORATORY
COSTS ACCOUNT FOR

~4%

OF HEALTH CARE COSTS;
LABORATORY TESTS

- SINGLE HIGHEST
VOLUME MEDICAL
ACTIVITY
- # TESTS RAPIDLY INCREASING

COSTS RISING

15-25%/year

- FASTER THAN OTHER
AREAS OF MEDICINE
- MOSTLY DUE TO
MOLECULAR TESTS

~45%

LABORATORY
TESTS
UNDERUTILIZED

~21%

LABORATORY
TESTS
UNNECESSARY

Rohr et al. PLoS One 2016;11:e0149856
Zhi et al. PLoS One. 2013;8(11):e78962
Riley. Clin Microbiol Newslett 2017;39:69-73
Lippi et al. Ann Transl Med 2017;5(4):82

WHO

Priority Pathogens List (for R&D of New Antibiotics)

Critical

- *Acinetobacter baumannii*, carbapenem-resistant
- *Pseudomonas aeruginosa*, carbapenem-resistant
- *Enterobacteriaceae*, carbapenem-resistant, 3rd generation cephalosporin resistant

High

- *Enterococcus faecium*, vancomycin-resistant
- *Staphylococcus aureus*, methicillin-resistant, vancomycin intermediate and resistant
- *Helicobacter pylori*, clarithromycin resistant
- *Campylobacter*, fluoroquinolone-resistant
- *Salmonella* spp., fluoroquinolone-resistant
- *Neisseria gonorrhoeae*, 3rd generation cephalosporin-resistant, fluoroquinolone-resistant

Medium

- *Streptococcus pneumoniae*, penicillin non-susceptible
- *Haemophilus influenzae*, ampicillin-resistant
- *Shigella* spp., fluoroquinolone-resistant

CDC

Urgent Threats

- Carbapenem-resistant *Acinetobacter*
- *Candida auris*
- *Clostridioides difficile*
- Carbapenem-resistant *Enterobacteriaceae*
- Drug-resistant *Neisseria gonorrhoeae*

Serious Threats

- Drug-resistant *Campylobacter*
- Drug-resistant *Candida*
- Extended-spectrum β -lactamase-producing *Enterobacteriaceae*
- Vancomycin-resistant Enterococci
- Multidrug-resistant *Pseudomonas aeruginosa*
- Drug-resistant nontyphoidal *Salmonella*
- Drug-resistant *Salmonella* serotype Typhi
- Drug-resistant *Shigella*
- Methicillin-resistant *Staphylococcus aureus*
- Drug-resistant *Streptococcus pneumoniae*
- Drug-resistant Tuberculosis

Concerning Threats


- Erythromycin-resistant group A Streptococcus
- Clindamycin-resistant group B Streptococcus

Watch List

- Azole-resistant *Aspergillus fumigatus*
- Drug-resistant *Mycoplasma genitalium*
- Drug-resistant *Bordetella pertussis*

Classic Diagnostic Paradigm

Is the patient's
clinical presentation
caused by an
infection?



What is (are) the
causative
pathogen(s)?



Which treatment
should be
administered?

Classic approach contributing to antimicrobial resistance
crisis and failing because of it...


Classic Diagnostic Paradigm

Is the patient's clinical presentation caused by an infection?

History/Physical (+)

Imaging (+)

Laboratory tests (+)



What is (are) the causative pathogen(s)?

Culture (+/-)

Serology (+/-)


Molecular diagnostics (+/-)



Which treatment should be administered?

Culture → AST (+)


New Diagnostics



Theranostics

- Think about diagnostics differently – answer the treatment question “up-front” 😊

Is the patient's
clinical presentation
caused by an
infection?



What is (are) the
causative pathogen(s) –
culturable or fastidious?
– and what treatment
should be given?




~~Which treatment should
be administered?~~

**Creative use of technology can help
... and fortunately, we are in a technology
revolution!**




Technology Revolution Proteomics





Technology Revolution

NAAT and Sequencing-Based Diagnostics






Technology Revolution: Microbial Real-Time PCR Assays Developed @ Mayo Clinic, 2000–2020

2000	Herpes simplex virus*
2001	<i>Bacillus anthracis</i>
	Cytomegalovirus*
	<i>Toxoplasma gondii</i> *
2002	<i>Bordetella pertussis/parapertussis</i> *
	<i>Streptococcus pyogenes</i>
	Enterovirus
	Varicella zoster virus*
2003	<i>Tropheryma whipplei</i> *
	<i>Babesia microti</i> *
	BK virus*
	<i>Ehrlichia/Anaplasma</i> species*
	Epstein–Barr virus (qualitative)*
	JC virus*
	<i>Borrelia burgdorferi</i> *
2004	<i>Bartonella</i> species*
	<i>vanA/vanB</i> *
	Parvovirus B19*
2005	Influenza A/B
	<i>Pneumocystis jirovecii</i>
	BK virus (quantitative)
	Epstein–Barr virus (quantitative)
	Human herpesvirus-6
	<i>Plasmodium</i> species
	West Nile virus
2007	<i>Clostridioides difficile</i>
	<i>Coccidioides immitis/posadasii</i>
	<i>Staphylococcus aureus</i>
	<i>Mycobacterium chelonae/abscessus</i>
2008	Adenovirus


2009	<i>Legionella</i> species
	<i>bla</i> _{KPC}
	<i>Mycobacterium tuberculosis</i> complex
2010	<i>Salmonella</i> species
	<i>Shigella</i> species
	<i>Campylobacter</i> species
	<i>Yersinia</i> species
	Shiga toxin
2011	<i>Mycoplasma genitalium</i>
	<i>Mycoplasma hominis</i>
	<i>Ureaplasma urealyticum/parvum</i>
	<i>Histoplasma/Blastomyces</i> species
2012	<i>Mycobacterium tuberculosis</i> complex species
2013	<i>Coxiella burnetii</i>
	<i>bla</i> _{NDM}
	<i>Mycoplasma pneumoniae</i>
2014	<i>Babesia</i> species
	<i>Borrelia mayonii</i>
2015	Microsporidia
2016	<i>Borrelia miyamotoi</i>
2017	<i>bla</i> _{OXA48-like}
	<i>bla</i> _{VIM}
	<i>Kingella kingae</i>
	<i>Acanthamoeba</i> species
	Free-living amoeba
	Norovirus
2020	<i>mecA</i>
	<i>Helicobacter pylori</i>
	<i>Candida auris</i>
	SARS coronavirus-2

Microorganisms marked by an asterisk (*) were detected with conventional PCR assays with Southern blot detection developed and deployed in the 1990s prior to conversion to real-time PCR assays






Technology Revolution Point of Care Diagnostics



Rapid Detection & Simultaneous Resistance Profiling

- **Xpert (Cepheid)**
 - **MRSA/SA Nasal Complete Assay, SSTI Assay**
 - **MTB/RIF Assay**
- **Detection and macrolide susceptibility prediction**
 - ***Mycoplasma pneumoniae***
 - ***Helicobacter pylori* detection (stool)**
- ***Neisseria gonorrhoeae* ciprofloxacin susceptibility prediction**

Futuristic Vision → Complex Infection



Integrated Multi-omic Analysis - Arthroplasty Failure
Patient name: John Doe Patient ID: 123456789
Specimen type(s): synovial fluid, periprosthetic tissue, sonicate fluid

Tests run: <u>Microbial Tests</u>	<u>Host Response Tests</u>
☒ Culture - aerobic and anerobic	☒ Histopathology
☒ Multiplex nucleic acid amplification	☒ Human cellularity profiling
☒ Shotgun metagenomic sequencing	☒ Human proteomic analysis
☒ 16S rRNA PCR/sequencing	☒ Human transcriptomic analysis
☒ Microbial transcriptomic analysis	

Results

- Likelihood of infection:95%
- Predicted cause:*Staphylococcus aureus*
- Resistance genes and mutations detected:*mecA*

Suggested treatment regimen:

•



Conclusions

- **Many current microbiology diagnostics antiquated, poorly used**
- **Technology revolution**
 - **Bringing major advances**
- **How to move to the future**
 - **Demonstration of value**
- **The deliverables**
 - **Improved health (patients, society, AMR)**
 - **Less impact of AMR**
 - **Changes to healthcare delivery**